Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas I Papadakis

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Melanoma Research|March 9, 2026
FGD1 guanine nucleotide exchange factor drives secondary resistance to BRAF inhibition in melanomaGuy Namir, Mounib Elchebly, Andreas I Papadakis, et al.
Aging|November 16, 2010
HDAC pharmacological inhibition promotes cell death through the eIF2α kinases PKR and GCN2Philippos Peidis, Andreas I Papadakis, Kamindla Rajesh, et al.
Diagnostics (Basel, Switzerland)|July 2, 2021
Sample Adequacy Control (SAC) Lowers False Negatives and Increases the Quality of Screening: Introduction of "Non-Competitive" SAC for qPCR AssaysIvan Brukner, Alex Resendes, Shaun Eintracht, et al.
Genesis (New York, N.Y. : 2000)|March 26, 2011
Development of transgenic mice expressing a conditionally active form of the eIF2α kinase PKRAndreas I Papadakis, Dionissios Baltzis, Ryan C Buensuceso, et al.
Diagnostics (Basel, Switzerland)|December 24, 2021
Importance of Adequate qPCR Controls in Infection ControlMatthew Oughton, Ivan Brukner, Shaun Eintracht, et al.
Diagnostic Microbiology and Infectious Disease|June 10, 2019
Laboratory-developed test for detection of acute Clostridium difficile infections with the capacity for quantitative sample normalizationIvan Brukner, Shaun Eintracht, Vincenzo Forgetta, et al.
Cell Cycle (Georgetown, Tex.)|January 10, 2014
Evidence for eIF2α phosphorylation-independent effects of GSK2656157, a novel catalytic inhibitor of PERK with clinical implicationsJothilatha Krishnamoorthy, Kamindla Rajesh, Farzaneh Mirzajani, et al.
Journal of Infection and Public Health|February 11, 2020
Maximizing confidence in a negative result: Quantitative sample adequacy controlIvan Brukner, Shaun Eintracht, Andreas I Papadakis, et al.
The Journal of Biological Chemistry|September 6, 2007
The eIF2alpha kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53Dionissios Baltzis, Olivier Pluquet, Andreas I Papadakis, et al.
The Journal of Biological Chemistry|December 8, 2007
PKR and PKR-like endoplasmic reticulum kinase induce the proteasome-dependent degradation of cyclin D1 via a mechanism requiring eukaryotic initiation factor 2alpha phosphorylationJennifer F Raven, Dionissios Baltzis, Shuo Wang, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Melanoma Research|March 9, 2026
FGD1 guanine nucleotide exchange factor drives secondary resistance to BRAF inhibition in melanomaGuy Namir, Mounib Elchebly, Andreas I Papadakis, et al.
Aging|November 16, 2010
HDAC pharmacological inhibition promotes cell death through the eIF2α kinases PKR and GCN2Philippos Peidis, Andreas I Papadakis, Kamindla Rajesh, et al.
Diagnostics (Basel, Switzerland)|July 2, 2021
Sample Adequacy Control (SAC) Lowers False Negatives and Increases the Quality of Screening: Introduction of "Non-Competitive" SAC for qPCR AssaysIvan Brukner, Alex Resendes, Shaun Eintracht, et al.
Genesis (New York, N.Y. : 2000)|March 26, 2011
Development of transgenic mice expressing a conditionally active form of the eIF2α kinase PKRAndreas I Papadakis, Dionissios Baltzis, Ryan C Buensuceso, et al.
Diagnostics (Basel, Switzerland)|December 24, 2021
Importance of Adequate qPCR Controls in Infection ControlMatthew Oughton, Ivan Brukner, Shaun Eintracht, et al.
Diagnostic Microbiology and Infectious Disease|June 10, 2019
Laboratory-developed test for detection of acute Clostridium difficile infections with the capacity for quantitative sample normalizationIvan Brukner, Shaun Eintracht, Vincenzo Forgetta, et al.
Cell Cycle (Georgetown, Tex.)|January 10, 2014
Evidence for eIF2α phosphorylation-independent effects of GSK2656157, a novel catalytic inhibitor of PERK with clinical implicationsJothilatha Krishnamoorthy, Kamindla Rajesh, Farzaneh Mirzajani, et al.
Journal of Infection and Public Health|February 11, 2020
Maximizing confidence in a negative result: Quantitative sample adequacy controlIvan Brukner, Shaun Eintracht, Andreas I Papadakis, et al.
The Journal of Biological Chemistry|September 6, 2007
The eIF2alpha kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53Dionissios Baltzis, Olivier Pluquet, Andreas I Papadakis, et al.
The Journal of Biological Chemistry|December 8, 2007
PKR and PKR-like endoplasmic reticulum kinase induce the proteasome-dependent degradation of cyclin D1 via a mechanism requiring eukaryotic initiation factor 2alpha phosphorylationJennifer F Raven, Dionissios Baltzis, Shuo Wang, et al.
Pageof 4